Overall, the proliferation rate (Ki67) was already low prior to treatment with a median of 2% (IQR 0.8–3%) and remained stable over time within the remaining viable tumor cells, with no differences between high-grade and low-grade MLS. The gene discussed is MKI67; the disease is neoplasm.